Methotrexate can cause brain fog, and the effect is well documented in both cancer and autoimmune disease settings. While the most severe cognitive problems tend to show up with high-dose or intrathecal methotrexate used in cancer treatment, people on the lower doses prescribed for rheumatoid arthritis and psoriasis report it too. The underlying biology involves folate disruption, a buildup of toxic byproducts in the brain, and persistent inflammation in brain cells that can outlast the treatment itself. Understanding why it happens opens the door to practical steps that can reduce or prevent it.
What Brain Fog From Methotrexate Actually Feels Like
The term “brain fog” is vague enough that it sometimes gets dismissed, but the cognitive complaints tied to methotrexate are specific and measurable. People describe difficulty concentrating, trouble retrieving words, feeling mentally sluggish, and struggling to juggle multiple tasks. In research settings, these map to deficits in working memory, spatial memory, and what neuroscientists call executive function: the ability to plan, switch between tasks, and adapt to new rules on the fly.
Animal studies have helped pin down the cognitive profile. In juvenile rats treated with methotrexate, researchers found persistent problems with pattern recognition and cognitive flexibility that lasted at least eight weeks after the final dose. The animals needed significantly more attempts to learn new rules in set-shifting tasks, which is roughly the rodent equivalent of struggling to multitask or adjust to changes in routine.1PubMed Central. Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model These weren’t subtle effects that faded quickly. The deficits stuck around long after the drug was out of the system, matching the complaints of patients who say their thinking never quite bounced back.
Patient surveys back this up. In a study comparing people taking methotrexate by mouth, by injection, and those on biologic drugs, mental fog was reported at notably higher rates in both methotrexate groups. Among those who did report it, the severity was worse in the methotrexate groups than in the biologic group.2PubMed Central. Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis So this is not a niche complaint. It shows up consistently when you ask patients the right questions.
How Methotrexate Disrupts Brain Chemistry
Methotrexate works by blocking folate metabolism. That is exactly why it kills rapidly dividing cancer cells and tamps down overactive immune responses. But the brain depends on folate too, and when methotrexate depletes it, a cascade of problems follows.
The first domino is a drop in folate levels in the fluid surrounding the brain. In rats given systemic methotrexate, researchers measured marked reductions in both blood and cerebrospinal fluid folate. This was paired with changes in the chemical balance of methylation, a process the brain uses to maintain and repair its cells.3Pharmacology Biochemistry and Behavior. Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats When folate drops, a byproduct called homocysteine piles up. Homocysteine is converted into excitatory amino acids that, in excess, can overstimulate and damage neurons. In children receiving methotrexate for cancer, cerebrospinal fluid levels of homocysteine were roughly four times higher than in untreated children, and two excitatory neurotransmitters that are normally undetectable were found in significant concentrations.4PubMed. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer
The second wave of damage involves the brain’s own immune cells, called microglia. Methotrexate directly activates these cells, pushing them into an inflammatory state. In a landmark study published in Cell, researchers showed that methotrexate-treated mice had roughly double the number of activated microglia in their white matter compared to controls, and this inflammation persisted for at least six months after the last dose.5PubMed Central. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment The same study demonstrated that when researchers depleted the inflammatory microglia, the downstream problems, including disrupted myelin (the insulation around nerve fibers) and cognitive deficits, were reversed. This is strong evidence that the neuroinflammation is not just a bystander but a direct driver of the brain fog.
Separate work confirmed this pattern, showing that methotrexate-treated rats had elevated markers of oxidative stress, inflammation, and cell death in the hippocampus, a brain region critical for memory.6PubMed Central. Apigenin Attenuates Hippocampal Microglial Activation and Restores Cognitive Function in Methotrexate-Treated Rats The picture that emerges is a drug that hits the brain on multiple fronts: it starves cells of folate, floods them with toxic metabolites, and triggers a long-running inflammatory process that damages the wiring between neurons.
Does the Dose Matter
The short answer is yes, a lot, but low-dose users are not entirely off the hook. The neurological side effects of methotrexate are primarily reported in patients receiving high-dose infusions or intrathecal injections, which are standard in the treatment of certain cancers. These patients can develop acute symptoms like severe headaches and drowsiness, subacute problems such as seizures and stroke-like episodes, and longer-term cognitive and behavioral difficulties.7British Journal of Hospital Medicine. Methotrexate neurological toxicities: current state-of-the-art The same review notes that neurotoxicity can occur even in patients on low-dose treatment, the kind prescribed weekly for rheumatoid arthritis or psoriasis, though it is less common and usually less severe.
Route of administration adds another wrinkle. The patient experience study mentioned earlier found that mental fog rates were highest among people receiving subcutaneous (injectable) methotrexate, compared to oral methotrexate or biologic alternatives. The researchers speculated this reflects higher drug levels in the blood with injections.2PubMed Central. Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis For people on low-dose methotrexate who are experiencing brain fog, this is worth discussing with a prescriber. Switching from injectable to oral, or adjusting the dose downward, could make a difference for some patients, though it involves balancing symptom control against cognitive side effects.
The Critical Role of Folinic Acid
Because the core mechanism of methotrexate’s brain toxicity starts with folate depletion, the most direct countermeasure is replacing the folate the drug strips away. In high-dose cancer treatment, this is already standard practice: patients receive folinic acid (also called leucovorin) as a “rescue” agent after methotrexate infusions. The evidence for its effectiveness is strong. A comprehensive review of neuropsychological studies concluded that inadequate folinic acid rescue was the cause of neurocognitive damage after high-dose methotrexate, and that adequate rescue prevents it.8Journal of Pediatric Hematology/Oncology. A Comprehensive Review of Neuropsychologic Studies Supports the Concept That Adequate Folinic Acid Rescue Prevents Post Methotrexate Neurotoxicity
Timing turns out to be crucial. A separate analysis of published data concluded that when folinic acid is given at a sufficiently high dose and started within 24 to 36 hours after the beginning of methotrexate exposure, virtually all forms of neurotoxicity can be prevented without compromising the drug’s therapeutic effect.9PubMed. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue This finding carries real clinical weight. It suggests that many cases of methotrexate-related brain fog in cancer patients are preventable, not with a new drug, but with more consistent application of rescue protocols that already exist.
For people on low-dose methotrexate for autoimmune conditions, folinic acid rescue at the scale used in cancer treatment is not standard. Instead, rheumatologists typically prescribe folic acid supplements (usually 1 mg daily or 5 mg weekly) to offset side effects including fatigue and gastrointestinal problems. The evidence that supplemental folic acid specifically prevents cognitive effects at low doses is thinner than the leucovorin data in oncology, but the logic is the same: replenishing folate counteracts the metabolic disruption that leads to brain symptoms. If you are on low-dose methotrexate and not already taking folic acid, that conversation with your doctor is one of the simplest and most evidence-backed things you can do.
Memantine and Other Protective Strategies
Beyond folinic acid, researchers have explored whether existing drugs can shield the brain during methotrexate treatment. The most promising candidate so far is memantine, a medication normally used for Alzheimer’s disease. In a rat study, animals that received memantine alongside intrathecal methotrexate had far fewer memory problems: the rate of spatial memory deficits dropped from 56% in the methotrexate-only group to 20% in the group that also received memantine.10PubMed Central. Memantine Protects Rats Treated with Intrathecal Methotrexate from Developing Spatial Memory Deficits Memantine works by blocking a type of glutamate receptor, which fits with the finding that methotrexate causes a buildup of excitatory neurotransmitters. By damping down that excitotoxic signal, memantine appears to protect neurons from the collateral damage.
This is still preclinical, meaning it has been shown in animals but not yet in large human trials. However, because memantine is already FDA-approved for another condition, it would be straightforward for clinicians to test in methotrexate patients if future studies confirm the benefit. Some oncologists already prescribe it off-label for chemotherapy-related cognitive impairment, though the evidence base remains limited.
Other protective approaches target the inflammatory side of the equation. The apigenin study mentioned earlier found that this flavonoid compound, found naturally in chamomile and parsley, reversed microglial activation and restored cognitive function in methotrexate-treated rats.6PubMed Central. Apigenin Attenuates Hippocampal Microglial Activation and Restores Cognitive Function in Methotrexate-Treated Rats That does not mean loading up on chamomile tea will fix the problem, but it highlights neuroinflammation as a target that future therapies could address.
Practical Steps If You Are Experiencing Brain Fog
Knowing the biology is useful, but what can you actually do right now if methotrexate is clouding your thinking? Here are the strategies with the strongest rationale behind them:
- Take your folate: If you are on low-dose methotrexate and not supplementing with folic acid, ask your prescriber about it. This is the single most mechanistically justified intervention. If you are on high-dose methotrexate for cancer, ensure your leucovorin rescue is being dosed and timed optimally.
- Report it early: Brain fog from methotrexate is often treatable, but only if your medical team knows about it. Some patients dismiss it or assume it is just part of being unwell. Bringing it up can prompt a dose review, a switch in administration route, or the addition of protective medications.
- Manage sleep aggressively: There is growing evidence that methotrexate-induced sleep disruption and cognitive impairment share the same underlying biology, both tied to glial cell dysfunction and impaired myelin integrity.11Oxford Academic (Sleep). Chemotherapy’s hidden side effect: sleepless nights without cancer Poor sleep worsens cognitive performance on its own, so addressing insomnia or disrupted sleep patterns could help break the cycle. Good sleep hygiene, consistent schedules, and treatment of any underlying sleep disorder become more important when you are on a drug that is already taxing the brain.
- Stay physically active: Aerobic exercise has the most consistent evidence for improving cognitive function across many contexts, including chemotherapy-related impairment. It promotes the growth of new brain cells in the hippocampus and reduces neuroinflammation, both of which are relevant to methotrexate’s effects.
- Use external supports: This is less glamorous than pharmaceutical interventions, but calendars, alarms, written lists, and structured routines can substantially reduce the functional impact of working memory deficits. The goal is not to fix the fog but to work around it while the underlying cause is addressed.
Why the Fog Persists After Stopping the Drug
One of the more frustrating aspects of methotrexate-related brain fog is that stopping the drug does not always make it go away quickly. The Cell study on tri-glial dysregulation found that microglial activation in the brain’s white matter persisted for at least six months after the final methotrexate dose in mice.5PubMed Central. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment The inflammatory microglia disrupted the cells responsible for producing myelin, leading to chronic under-insulation of nerve fibers. When the researchers eliminated the activated microglia, myelin production recovered and cognitive performance improved, suggesting the brain was not permanently damaged but was being held in a dysfunctional state by ongoing inflammation.
This has an encouraging implication: the fog is potentially reversible if the inflammation can be turned off. It also explains why some cancer survivors report cognitive improvement months or even years after treatment ends, as the inflammatory process slowly resolves on its own. For people who have stopped methotrexate and are still struggling with cognition, this is reason for cautious optimism rather than resignation. The damage pattern is more like a smoldering fire than a burned-down building.
The Surprisingly Large Role of Expectations
There is a psychological dimension to methotrexate side effects that most patients never hear about. In a randomized trial, rheumatology patients starting methotrexate were split into two groups. One group received a standard information sheet about the drug. The other received a “mindset intervention” that reframed how they thought about the medication and its side effects. At the four-week follow-up, only about 4% of the mindset group reported not taking their methotrexate as prescribed, compared to 39% in the standard information group.12PubMed Central. Changing mindsets about methotrexate in the rheumatology clinic to reduce side effects and improve adherence
This does not mean brain fog is “all in your head.” The biological mechanisms are real and well characterized. But the nocebo effect, where expecting side effects makes you more likely to experience them, is a documented phenomenon with methotrexate. If you start the drug already convinced it will impair your thinking, you are more likely to notice and attribute everyday lapses to the medication, creating a feedback loop that amplifies distress. The practical takeaway is not to ignore genuine cognitive changes, but to give the drug a fair trial without assuming the worst. Patients who approach the treatment with a balanced understanding of both benefits and risks appear to do better, both in terms of sticking with the medication and in terms of the side effects they actually experience.
When the Evidence Gets Complicated
It would be tidy if the research unanimously pointed to a single, clear mechanism for methotrexate brain fog, but it does not quite work that way. While the tri-glial dysregulation model from the Cell paper is compelling and widely cited, other researchers have found some inconsistencies. One earlier review noted that while methotrexate did increase the number of active microglia in the hippocampus, the expected rise in inflammatory cytokines was not always detected, and brain-imaging markers of microglial activation did not always match what was seen under the microscope.13Frontiers. Mechanisms of chemotherapy-induced behavioral toxicities Some findings even suggested methotrexate reduced certain inflammatory markers in the bloodstream, which complicates the straightforward “neuroinflammation causes fog” narrative.
What this likely means is that multiple mechanisms contribute. Folate depletion and homocysteine toxicity might dominate in some patients, while persistent microglial activation matters more in others. Myelin damage, oxidative stress, and disrupted neurotransmitter balance probably all play roles to varying degrees depending on dose, duration, route, and individual biology. For the person experiencing the fog, the practical consequence is that no single intervention will work for everyone. The combination approach of folate supplementation, sleep optimization, exercise, and open communication with prescribers makes more sense than banking on any one fix, precisely because the problem itself is multi-layered.
The field is also still catching up to patients on low-dose methotrexate. Most of the mechanistic research has been done in high-dose or intrathecal settings, where the effects are more dramatic and easier to study. The millions of people taking 10 to 25 milligrams per week for autoimmune conditions represent a population whose cognitive complaints are real but harder to isolate from disease-related fatigue, pain-related concentration problems, and the general mental load of chronic illness. Better-designed studies in this group are needed before anyone can say with precision how common brain fog is at low doses and what the best countermeasures are.